ANGLE plc (GB:AGL) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
ANGLE plc has entered into an agreement with NuProbe to attain an exclusive license for a next-generation sequencing (NGS) assay, enhancing the capabilities of its liquid biopsy technology, Parsortix. The NGS panel, which facilitates the analysis of both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) from a single blood sample, promises to advance cancer treatment personalization. This collaboration aims to bolster ANGLE’s pharma services and offer clinicians tools for ongoing monitoring of tumor dynamics and patient response to therapies.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.